Navigation Links
Sinobiopharma Secures Rights to Seven Key Patents
Date:4/27/2009

NANJING, China, April 27 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders. The patents that will significantly enhance Sinobiopharma's ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.

The patents are for the following:

  1. Synthesis of amantadine hydrochloride
  2. Method for preparation of 17-acylsinomenine derivatives
  3. Preparation of 17-sulfonylsinomenine
  4. Preparation of N-substituted sinomenine
  5. Method for preparation of Sinomenine compound having dextro-rotary C ring-deficient morphinan skeleton
  6. Synthesis of Eplerenone from 11 -hydroxycanrenone
  7. Method for resolving tetrahydroisoquinoline racemate

Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
2. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
5. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
6. Aerovance Secures $38 Million in Equity Financing
7. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
8. Pearl Therapeutics Secures $8 Million in Debt Financing
9. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Northwest Biotherapeutics Secures $700,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Summit ... (NSCF) to support the development of a patient-specific stem cell therapy for the treatment ... the lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, ...
(Date:4/29/2016)... 29, 2016 Elekta is pleased ... to its industry-leading treatment planning software, is available for ... Monaco version 5.11 provides significant performance speed ... speeds up to four times faster than in previous ... industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... Q BioMed Inc. (OTCQB:QBIO), ...  was featured in an article he wrote on ... To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... an essential business journal for life science executives ... Big Pharmas. Their content is designed to inform ...
(Date:4/28/2016)... ... 28, 2016 , ... Next week on May 5 at ... technologies for tissue stem cell counting and expansion to gene-editing scientists and other ... CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing scientists ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics as a Service ... --> Research and Markets ...
Breaking Biology News(10 mins):